Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors
- PMID: 35180829
- PMCID: PMC9271331
- DOI: 10.1089/thy.2022.0095
Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors
Conflict of interest statement
No competing financial interests exist.
Comment on
-
Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.Thyroid. 2022 May;32(5):544-551. doi: 10.1089/thy.2021.0418. Epub 2022 Jan 11. Thyroid. 2022. PMID: 34894720
Similar articles
-
Accumulation of 131Iodine in the nasolacrimal sac/duct after radioiodine therapy for papillary thyroid cancer.J Pak Med Assoc. 2023 Mar;73(3):713-714. doi: 10.47391/JPMA.23-22. J Pak Med Assoc. 2023. PMID: 36932793
-
Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.Ophthalmic Plast Reconstr Surg. 2015 May-Jun;31(3):e50-2. doi: 10.1097/IOP.0000000000000066. Ophthalmic Plast Reconstr Surg. 2015. PMID: 24836449
-
Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.Ann Nucl Med. 2007 Nov;21(9):525-7. doi: 10.1007/s12149-007-0056-5. Epub 2007 Nov 26. Ann Nucl Med. 2007. PMID: 18030585
-
Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO).Prog Retin Eye Res. 2023 Sep;96:101193. doi: 10.1016/j.preteyeres.2023.101193. Epub 2023 Jul 1. Prog Retin Eye Res. 2023. PMID: 37394093 Review.
-
Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know.Ophthalmic Plast Reconstr Surg. 2016 Jul-Aug;32(4):243-8. doi: 10.1097/IOP.0000000000000647. Ophthalmic Plast Reconstr Surg. 2016. PMID: 26866333 Review.
References
-
- Moore MD, Postma E, Gray KD, Ullmann TM, Hurley JR, Goldsmith S, Sobel VR, Schulman A, Scognamiglio T, Chritos PJ, Hassett E, Luick J, Whitehall D, Zarnegar R, Fahey TJ. 2018. Less is more: the impact of Multidisciplinary Thyroid Conference on the treatment of well-differentiated thyroid carcinoma. World J Surg 42:343–349. - PubMed
-
- Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP. 2013. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23:683–694. - PubMed
-
- Singer MC, Marchal F, Angelos P, Bernet V, Boucai L, Buchholzer S, Burkey B, Eisele D, Erkul E, Faure F, Freitag SK, Gillespie MB, Harrell RM, Hartl D, Haymart M, Leffert J, Mandel S, Miller, BS, Morris J, Pearce EN, Rahmati R, Ryan WR, Schaitkin B, Schlumberger M, Stack BC, Van Nostrand D, Wong KK, Randolph G. 2020. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. Head Neck 42:3446–3459. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical